Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Expected to develop neutropenia (absolute neutrophil count less than 500/mm\^3) lasting for more than 10 days after chemotherapy for 1 of the following conditions:
• •* Leukemia
• •* Lymphoma
• •* Aplastic anemia
• •* Preparation for a bone marrow or stem cell transplantation
• •Requiring treatment for the prevention of systemic fungal infection
• •PATIENT CHARACTERISTICS:
• •Age
• •2 to 11
• •Performance status
• •Not specified
• •Life expectancy
• •More than 3 months
• •Hematopoietic
• •See Disease Characteristics
• •Hepatic
• •AST and ALT no greater than 5 times upper limit of normal (ULN)
• •Bilirubin no greater than 5 times ULN
• •Renal
• •Creatinine clearance at least 30 mL/min
• •Cardiovascular
• •No cardiac arrhythmia
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •No severe hypokalemia (potassium less than 3.2 mmol/L)
• •No prior hypersensitivity to or severe intolerance of azole antifungal agents
• •No other concurrent condition that would preclude study therapy
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •See Disease Characteristics
• •Chemotherapy
• •See Disease Characteristics
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified
• •Other
• •At least 24 hours since prior use of any of the following:
• •* Terfenadine
• •* Pimozide
• •* Quinidine
• •* Astemizole
• •* Cisapride
• •* Omeprazole
• •More than 14 days since prior use of any of the following:
• •* Rifampin
• •* Rifabutin
• •* Carbamazepine
• •* Phenytoin
• •* Nevirapine
• •* Long-acting barbiturates
• •No prior sirolimus
• •No prior enrollment on this study
• •No concurrent use of any of the following:
• •* Terfenadine
• •* Pimozide
• •* Quinidine
• •* Astemizole
• •* Cisapride
• •* Omeprazole
• •No other concurrent investigational drugs except any of the following:
• •* Drugs used as treatment for cancer
• •* Antiretroviral agents
• •* Drugs used for the treatment of any AIDS-defining opportunistic infections
• •No concurrent enrollment in investigational anticancer drug trials that exclude the use of other investigational agents